New arthritis pill shows promise for patients who failed standard therapy
NCT ID NCT07452445
First seen Mar 12, 2026 · Last updated May 20, 2026 · Updated 6 times
Summary
This study tests a new daily pill called ivarmacitinib for people with rheumatoid arthritis who did not get better with standard treatments. The drug works by blocking inflammation signals in the body. Researchers will check if it reduces joint pain and swelling after 12 weeks, and look at its safety. About 100 adults with moderate to severe arthritis will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.